Sanofi's dengue fever vax progresses in Thai trial

Reuters reports today that Sanofi's experimental vaccine for dengue fever, the most advanced its kind, is making progress in a Thai trial. The vaccine, which is on track to be available in 2014, is being tested in 15 countries, and initial results are expected at the end of next year. "It's very promising. The vaccine has been shown to be safe," Arunee Sabcharoen, an emeritus professor of tropical pediatrics at Mahidol University in Bangkok and the lead investigator in the Thai study, said, as quoted by Reuters. This could be the first vaccine for dengue fever, which affects about 220 million people each year around the world. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.